2024
Barriers to Clinical Trial Implementation Among Community Care Centers
Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia N, Zengin Z, Meza L, Chawla N, Castro D, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer R, Boehmer L, Pal S, Chehrazi-Raffle A. Barriers to Clinical Trial Implementation Among Community Care Centers. JAMA Network Open 2024, 7: e248739. PMID: 38683608, PMCID: PMC11059033, DOI: 10.1001/jamanetworkopen.2024.8739.Peer-Reviewed Original ResearchConceptsClinical trial implementationClinical trial enrollmentTrial enrollmentUnmet needsCancer clinical trial enrollmentHealth care practicesPatients seeking careTrial implementationCommunity care centersCommunity oncology settingNational survey studyRural practiceClinical research opportunitiesCare practicesCare settingsCancer clinicOncology settingLimited staffingPractice changeRural settingsOncology clinicMain OutcomesHispanic residentsReferral practicesTrial participants
2023
Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers
Gebrael G, Zengin Z, Swami U. Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. JCO Precision Oncology 2023, 7: e2300397. PMID: 37972335, DOI: 10.1200/po.23.00397.Peer-Reviewed Original ResearchChanges in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety Scale
2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
Chawla N, Sayegh N, Tripathi N, Govindarajan A, Zengin Z, Phillip E, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal S, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2022, 21: 69-75. PMID: 36509613, DOI: 10.1016/j.clgc.2022.11.007.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall response rateTumor mutational burdenOverall survivalWorse OSPrimary diseaseMultivariate analysisMedian progression-free survivalImmune checkpoint inhibitor therapyInferior progression-free survivalPromoter mutationsWorse progression-free survivalCheckpoint inhibitor therapyMedian overall survivalImmune checkpoint inhibitorsTertiary cancer centerClinical prognostic factorsPrimary tumor siteTERT promoter mutationsCheckpoint inhibitorsInhibitor therapyLaboratory parametersPrognostic factorsCancer CenterFemale sexNivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2022, 28: 704-712. PMID: 35228755, PMCID: PMC9018425, DOI: 10.1038/s41591-022-01694-6.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaCell carcinomaCheckpoint inhibitorsResponse rateGut microbiomePoor-risk diseaseTreatment-naive patientsSingle-center studyPhase 1 trialRandomized phase 1 trialSignificant differencesBifidobacterium sppMechanism of actionNivolumab-ipilimumabSarcomatoid histologyPrimary endpointSecondary endpointsImmune compartmentStudy armsClinical outcomesClear cellsClinical observationsPatients
2021
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
Zengin Z, Chehrazi-Raffle A, Salgia N, Muddasani R, Ali S, Meza L, Pal S. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology Seminars And Original Investigations 2021, 40: 25-36. PMID: 34840077, DOI: 10.1016/j.urolonc.2021.10.003.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUrothelial carcinomaCheckpoint inhibitorsTargeted therapyLower tract diseaseMultiple disease stagesMetastatic urothelial carcinomaOverall response rateAntibody-drug conjugatesGrowth factor receptor familyFGFR3 inhibitionUC tumorsChemotherapy regimensUpper tractOngoing trialsDisease stageTract diseaseTreatment paradigmFactor receptor familyHigh incidenceActionable mutationsFGFR1-4FGFR3 inhibitorsSmall molecule inhibitorsFGFR3 mutationsCharacterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
Salgia NJ, Chehrazi‐Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine 2021, 10: 5671-5680. PMID: 34331372, PMCID: PMC8366095, DOI: 10.1002/cam4.4119.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAttitude of Health PersonnelCaliforniaCancer Care FacilitiesClinical Trials as TopicCommunicationFemaleHospitals, CommunityHumansIntersectoral CollaborationMaleMiddle AgedNeoplasmsOncologistsReferral and ConsultationSurveys and QuestionnairesTertiary Care CentersConceptsClinical trialsCommunity oncologistsTertiary centerTrial availabilityClinical trial availabilityTertiary cancer centerClinical trial enrollmentRegional tertiary centerCancer providersMost patientsTertiary referralMedical oncologistsReferral patternsTrial enrollmentCancer CenterTertiary practiceCancer carePatient referralMost oncologistsGeneral oncologistsCommon reasonClinical practiceOncologistsPatient careClinical expertiseComplementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCell-free tumor DNARenal cell carcinomaGenomic profilingCell carcinomaTissue-based testingTumor DNA (ctDNA) assessmentClinical Laboratory Improvement AmendmentsActionable alterationsCtDNA profilingCtDNA assessmentPatientsTumor DNAUnique alterationsAlteration frequencyCarcinomaDNA assessmentBloodGreater temporal separationTissueAlterationsConcordancePrevious findingsMutationsConcordance analysis